Press Room

Event

Guy Villax speaker at 2017 PDA/FDA Conference

Start

Monday, September 11, 2017 - 10:45

End

Monday, September 11, 2017 - 11:45

Location: Washington DC, United States

Presentation Title: Investing in Quality to Meet Business Objectives
10:45 a.m. – 11:15 a.m.

Guy Villax

Non-Executive Board Member

Degree in Accounting and Financial Management

Guy Villax has a degree in Management from the University College at Buckingham, UK.

Guy Villax was Hovione's Chief Executive from 1997 to 2022, having previously worked at Price Waterhouse in London and Hovione in Asia.

Guy holds leadership positions at industry associations and in Portuguese state organizations: Rx-360, Health Cluster Portugal, Portugal’s Business Roundtable; and the ANI (Portugal’s National Innovation Agency) and the CNCTI (National Council for Science, Technology and Innovation).

Session: Current Quality Challenges for Pharmaceutical Executives
As the biopharmaceutical industry continues to evolve, major challenges associated with globalization and complexity of the supply chain emerge. In addition, companies now face internal pressures related to the cost of medicines, dealing with various global regulatory frameworks and changing expectations in evolving healthcare systems. The challenges have led an industry drive to adopt new business and quality technologies and to pursue partnerships with global regulators to help companies understand and facilitate implementation of changing regulations. This session will focus on major challenges that quality professionals should be aware as they interact with executives at their firms, how ensuring quality can play a part in overcoming those challenges and the crucial role of the executive in driving quality within the company.

The 2017 PDA/FDA Joint Regulatory Conference is the premier pharmaceutical manufacturing event where you can engage directly with U.S. FDA representatives and industry experts! Over two and a half information-packed days, FDA regulators will provide updates on current efforts affecting the development of global regulatory strategies, and industry experts will present case studies illustrating how they use global strategies to improve the quality of medical products. Hear what the Conference Co-chairs and past attendees have to say about this exciting event!

Live from PDA/FDA: Culture of Quality

Empowering employees with a strong sense of ownership can lead to improved outcomes and increased cost efficiency.

You might be also interested in:

Also in the Press Room

See All

International pharmaceutical contract development and manufacturing organisation (CDMO) Hovione has today officially commissioned an expansion at its manufacturing facility in Ringaskiddy. The multi-million euro investment almost doubles the capacity of Hovione’s spray drying facilities in Ireland and will create more than 20 new positions. Hovione said this latest investment reinforces the company's position as a global leader in spray drying for pharma applications. This manufacturing technology, the company explained, is "especially important for inhalable therapies and oral medications with low bioavailability, enabling more effective treatments". Deputising for the Mayor of the County of Cork, councillor Audrey Buckley said: “I am delighted to welcome this very significant investment and the creation of further highly skilled jobs in Cork today. “It reinforces Hovione’s commitment to the region and the innovative solutions it provides to the pharmaceutical industry in Ireland.” Meanwhile Michael McGrath, the European Commissioner-Designate for Democracy, Justice and the Rule of Law, welcomed the expected jobs boost the expansion is to create. “This latest investment highlights the success of Hovione’s facility in Ringaskiddy, and underlines the continued resilience of Ireland’s pharmaceutical manufacturing sector. “I am delighted that Hovione will be shortly welcoming new team members to this expanded facility, and I wish both them and Hovione every success”. Jean-Luc Herbeaux, Hovione's chief executive said: “This newly opened facility further strengthens Hovione's position as the global CDMO of choice for spray drying development and manufacturing services. “It also underscores our commitment to bringing first-in-class technology and world-leading manufacturing services to Irish shores. “Ireland provides a superior environment for pharmaceutical manufacturing, and we are delighted to be a part of it.” CEO of IDA Ireland, Michael Lohan, said Hovione "has made a significant contribution both locally and nationally through employment and investment alike". "We warmly welcome Hovione’s commitment to investing in Cork and we wish them continued success," he added. Read the full article on EchoLive.ie

Press Clipping

EchoLive, 25 November 2024

Pharma company announces expansion of Cork facility to create more than 20 new jobs

Nov 25, 2024

Pharmaceutical contract development and manufacturing company Hovione has officially commissioned an expansion at its manufacturing facility in Ringaskiddy, Cork. Announcing the development on Monday, the multi-million euro investment almost doubles the capacity of Hovione’s spray drying facilities in Ireland and will create more than 20 new positions. This manufacturing technology is especially important for inhalable therapies and oral medications with low bioavailability, enabling more effective treatments, the company said. Deputising for the Mayor of the County of Cork, Cllr. Audrey Buckley said: “I am delighted to welcome this very significant investment and the creation of further highly skilled jobs in Cork today. "It reinforces Hovione’s commitment to the region and the innovative solutions it provides to the pharmaceutical industry in Ireland.” Michael McGrath, the European Commissioner-Designate for Democracy, Justice and the Rule of Law said: “This latest investment highlights the success of Hovione’s facility in Ringaskiddy, and underlines the continued resilience of Ireland’s pharmaceutical manufacturing sector. "I am delighted that Hovione will be shortly welcoming new team members to this expanded facility, and I wish both them and Hovione every success”. This latest investment builds on the momentum of the recently announced spray drying capacity expansion at the Company's East Windsor, New Jersey, site. Jean-Luc Herbeaux, Hovione´s Chief Executive said: “This newly opened facility further strengthens Hovione´s position as the global CDMO of choice for spray drying development and manufacturing services. "It also underscores our commitment to bringing first-in-class technology and world-leading manufacturing services to Irish shores. Ireland provides a superior environment for pharmaceutical manufacturing, and we are delighted to be a part of it.” IDA chief executive Michael Lohan said the company has made a significant contribution both locally and nationally, adding: "I am pleased to be here today to mark another step on that journey. We warmly welcome Hovione’s commitment to investing in Cork and we wish them continued success.” Read the full article on IrishExaminer.com

Press Clipping

Irish Examiner, 25 November 2024

Pharma company Hovione to double capacity at Cork site as part multi-million euro investment

Nov 25, 2024

Hovione’s Eunice Costa Shares Insights on Inhaled Medicine Formulation in Pharmaceutical Technology eBook The demand for efficient inhalation therapies is higher than ever. At Hovione we are focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes. To learn more about or work, do not miss the contribution of Eunice Costa, our R&D Director for Inhalation & Advanced Drug Delivery, in the latest Pharmaceutical Technology eBook – “Trends in Formulation”. In her interview, Eunice discusses key challenges and considerations in formulating inhaled medicines, emphasizing the importance of excipient selection, device compatibility, and patient-centric design for successful drug delivery to the lungs. With respiratory diseases at the forefront, especially following the COVID-19 pandemic, the demand for efficient inhalation therapies is higher than ever. Eunice sheds light on how Hovione is tackling these demands by focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes. Explore Eunice Costa’s full insights on this crucial area of drug development in Pharmaceutical Technology's September 2024 eBook. This resource provides an in-depth look into the complexities of inhaled drug formulations and the exciting innovations shaping the future of respiratory treatments. Read the full article at Pharmaceutical Technology eBook Read the Trends in Formulation eBook at PharmTech

Article

Excipient and delivery device selection play crucial roles in the formulation of inhaled drugs.